Patient Education/ Marketing: Keeping Pace with Patients

Welcome to patient education circa 2014: With patient expectations at an all-time high, pharma marketers are struggling to keep up in the quest to make ...

Why Pharma Should Stop Marketing Products and Start Marketing Services

Today, we're all still trying to get people to buy our drugs and be a trusted health advisor, but these two goals seem to be ...

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. ...

To Expand Their Appeal, Children's Hospitals Need to Sharpen Their Focus

To find stability, children's hospitals must offer value to today's more empowered healthcare consumers. This requires building strong relationships with moms—specifically millennial moms.

Leadership Exchange: How Do We Get Beyond the Pill?

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts ...

BMS striving to push Opdivo past Keytruda

Keytruda was the first of the new PD-1 class of immuno-oncology drugs to reach the US, but Bristol-Myers Squibb and Ono could run away with ...

Latest

OPDP slams cholesterol drug's e-mail claims

OPDP slams cholesterol drug's e-mail claims

The Office of Prescription Drug Promotion took aim at Cipher Pharmaceuticals and its marketer Kowa, in an Untitled Letter over an e-mail alert making what it said were unsubstantiated assertions.

Lawmakers float generic drug legislation

The bill proposes fining branded drugmakers for not complying.

Auxilium turns down Endo, leaves door open

Auxilium turns down Endo, leaves door open

The Chesterbrook, PA, drug manufacturer announced Monday Endo's unsolicited $2.2-billion bid undervalued the company.

Five things for pharma marketers to know: Monday, September 22

Five things for pharma marketers to know: Monday, September 22

GSK releases polio-infected water into Lasne River in Belgium; House reps Burgess and Schwartz introduce CME exemption bill for Sunshine Act; NIH and FDA announce plan to create facebook-esque catalogue of oral-drugs.

Five things for pharma marketers to know: Friday, September 19

Five things for pharma marketers to know: Friday, September 19

Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.

FDA panel votes against taking drugs for "low-T"

FDA panel votes against taking drugs for "low-T"

An FDA advisory panel voted overwhelmingly against the use of testosterone-replacement drugs for "low-T" Wednesday, saying the label should narrow and that more safety information is needed.

Missing generic hurts Rite Aid

The drugstore chain has lowered its forecast, and generics are just one reason.

Novartis NY layoffs coming

Plans to unwind the Suffern, NY, site move forward this winter.

Merck's weekly DPP-IV on par with daily Januvia: study

Merck's weekly DPP-IV on par with daily Januvia: study

Merck unveiled the DPP-IV clinical trial results at the European Association for the Study of Diabetes Annual meeting Thursday.

Five things for pharma marketers to know: Thursday, September 18

Five things for pharma marketers to know: Thursday, September 18

FDA panel votes overwhelmingly against Low-T drugs; Stenda approved for fast-acting ED treatment; and Bayer hones life-sci focus, spins off material sciences business.

MM&M AWARDS GALLERY

A Star-Studded Evening

Click on the image at the left to see a gallery of images from the 2013 MM&M Awards dinner

Agency Spotlight


Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.